psoriasis

Search with Google Search with Bing
Information
Disease name
psoriasis
Disease ID
DOID:8893
Description
"A skin disease that is characterized by patches of thick red skin and silvery scales." [url:https\://www.cdc.gov/psoriasis/index.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT03818035 Active, not recruiting Phase 3 A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis February 8, 2019 July 21, 2025
NCT03737045 Active, not recruiting N/A Psoriatic Arthritis and Psoriasis Treatment Decision Aid December 1, 2018 December 31, 2024
NCT04435600 Active, not recruiting Phase 3 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms July 14, 2020 December 16, 2024
NCT03662685 Active, not recruiting Phase 4 Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris August 1, 2018 May 31, 2024
NCT00508547 Active, not recruiting Psoriasis Longitudinal Assessment and Registry June 21, 2007 December 31, 2030
NCT03465696 Active, not recruiting N/A A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis May 14, 2018 June 2024
NCT06301997 Active, not recruiting Phase 2 A Herbal Compound for Psoriasis February 1, 2023 December 30, 2024
NCT05701995 Active, not recruiting Phase 4 A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting January 31, 2023 May 27, 2025
NCT05645627 Active, not recruiting Phase 3 A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis February 10, 2023 April 10, 2025
NCT04340076 Active, not recruiting Phase 4 Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis August 20, 2020 December 2025
NCT06066125 Active, not recruiting Phase 3 A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis March 31, 2023 October 2024
NCT05283135 Active, not recruiting Phase 2 High Dose Risankizumab for Psoriasis March 1, 2022 July 2024
NCT04200690 Active, not recruiting N/A Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory Diseases January 14, 2020 January 31, 2024
NCT06005792 Active, not recruiting Phase 1 Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis October 10, 2022 May 2026
NCT06125808 Active, not recruiting Phase 2 Efficacy and Safety Study of HRO350 in Patients With Mild-to-moderate Psoriasis (the 'HeROPA' Study). May 25, 2023 February 25, 2025
NCT04175613 Active, not recruiting Phase 3 A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis December 20, 2019 February 22, 2027
NCT05604898 Active, not recruiting Phase 2 A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis April 1, 2021 August 2023
NCT06357221 Active, not recruiting Phase 4 A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients April 8, 2024 July 31, 2024
NCT05478499 Active, not recruiting Phase 4 Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis October 6, 2022 October 24, 2024
NCT05185258 Active, not recruiting Phase 4 Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study February 16, 2022 November 15, 2025
NCT03451851 Active, not recruiting Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants July 11, 2018 December 18, 2026
NCT03168347 Active, not recruiting N/A Assessing Patient Confidence in Biologic Medications June 1, 2017 June 2024
NCT03791216 Active, not recruiting Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment December 1, 2018 December 2024
NCT06275659 Active, not recruiting N/A An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis December 4, 2023 March 18, 2024
NCT02829424 Active, not recruiting Phase 4 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis January 23, 2017 February 10, 2024
NCT05110313 Active, not recruiting Phase 4 Effects of Tildrakizumab on Epigenetic Age April 8, 2022 August 1, 2024
NCT05056168 Active, not recruiting Validation of a Dermatology-Specific Treatment Satisfaction Instrument November 13, 2021 December 2023
NCT05858099 Active, not recruiting The Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis January 30, 2020 December 31, 2030
NCT02786186 Active, not recruiting A Registry of Patients With Moderate to Severe Plaque Psoriasis December 23, 2015 December 31, 2025
NCT04058652 Active, not recruiting N/A Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study) August 7, 2019 December 2024
NCT05730725 Active, not recruiting Phase 2 A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis April 3, 2023 May 30, 2024
NCT02775500 Active, not recruiting Apremilast Pregnancy Exposure Registry November 2014 July 2025
NCT02413801 Active, not recruiting Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients March 19, 2015 December 2023
NCT04036435 Active, not recruiting Phase 3 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis August 12, 2019 July 26, 2026
NCT00131066 Completed Long-Term Follow-Up Study of Psoriasis Patients August 2002 December 2007
NCT00134394 Completed Phase 2 Etanercept With Tacrolimus for Psoriasis February 2005 December 2007
NCT00143806 Completed Phase 2 Transitioning From Cyclosporine to Alefacept in Psoriasis October 2003 May 2007
NCT00147329 Completed Phase 2 Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis September 2005 July 2006
NCT00150982 Completed Phase 2 Alefacept Mechanism of Action in Psoriasis September 2003 February 2005
NCT00151008 Completed Phase 2 Bexarotene With Narrow-Band UVB for Psoriasis November 2003 August 2005
NCT00156247 Completed Phase 2 Acitretin and Etanercept in Psoriasis September 2005 March 2009
NCT00161655 Completed Phase 4 Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis April 2005 December 2006
NCT00162825 Completed Role of CD7 in Skin Inflammation and Psoriasis January 2004 December 2006
NCT00167752 Completed Psychiatric Problems in Chronic Skin Diseases December 2002
NCT00192452 Completed Phase 2 Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis March 2001 December 2001
NCT00192517 Completed Phase 2 Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis December 2003 September 2004
NCT00195507 Completed Phase 4 Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis December 2004 February 2007
NCT00195676 Completed Phase 3 Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis May 2004 October 2009
NCT00205465 Completed Phase 2 Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 December 2004 September 2005
NCT00230529 Completed Phase 2 A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis January 2003
NCT00234728 Completed N/A Study of a New Dressing for Use With Topical Medications September 2005 June 2007
NCT00235625 Completed Phase 2 Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris October 2005 November 2007
NCT00235820 Completed Phase 3 Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis July 2005
NCT00236119 Completed Phase 2 Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis June 2005 October 2007
NCT00237887 Completed Phase 3 Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis December 2004
NCT00244842 Completed Phase 3 Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis December 2004 October 2005
NCT00249808 Completed Phase 4 A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies December 13, 2004 January 25, 2007
NCT00251641 Completed Phase 3 The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED) September 1, 2005 June 1, 2008
NCT00254982 Completed Phase 3 Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED) August 2005 September 2006
NCT00258713 Completed Phase 3 A 36-Week Extension to Protocol ISA04-03 September 2005 July 2006
NCT00261976 Completed A Long-term Safety Study of Infliximab (Remicade) February 2002 March 2012
NCT00267969 Completed Phase 3 A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis December 2005 May 2011
NCT00279162 Completed Phase 3 Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis December 2005 July 2007
NCT00287118 Completed Phase 4 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis October 27, 2004 May 30, 2006
NCT00292396 Completed Phase 2 Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis November 2005 April 2008
NCT00293709 Completed Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists January 2006 February 2013
NCT00293722 Completed Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists January 2006 February 2013
NCT00293891 Completed Phase 3 A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis January 2007
NCT00293917 Completed Phase 3 A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis January 2006 August 2007
NCT00293930 Completed Phase 3 A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis November 2006
NCT00301002 Completed Phase 2 Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis June 2005 October 2006
NCT00307437 Completed Phase 3 A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis May 2005 October 2011
NCT00312026 Completed Phase 4 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet March 30, 2006 November 28, 2006
NCT00317499 Completed Phase 3 Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis April 2000 July 2002
NCT00320216 Completed Phase 2 A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis November 2003 March 2005
NCT00322439 Completed Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis May 1, 2006 February 8, 2013
NCT00329303 Completed Phase 2 Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis April 2006 May 2007
NCT00332332 Completed Phase 4 Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis March 2006 February 2010
NCT00333034 Completed Phase 3 Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis June 2006 May 2007
NCT00333411 Completed Phase 2 Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis June 2006
NCT00336973 Completed Phase 4 A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent May 2006
NCT00338143 Completed Phase 3 A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies October 2003 May 2004
NCT00338754 Completed Phase 2/Phase 3 Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis November 2005
NCT00341809 Completed Genetic Analysis of Psoriasis and Psoriatic Arthritis July 30, 2004 September 4, 2012
NCT00358384 Completed Phase 1 Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 September 26, 2005 February 24, 2006
NCT00368654 Completed Phase 1/Phase 2 Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy January 2007 May 2008
NCT00368784 Completed T Cell Repertoire Analysis of Immune Mediated Skin Diseases January 2007 November 2020
NCT00371163 Completed Molecular and Cellular Characterization of Spongiotic Dermatitis September 2006 December 2012
NCT00373516 Completed Phase 2 Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis September 2004 March 2005
NCT00384098 Completed Phase 2 Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis September 2006 May 2007
NCT00395941 Completed Phase 2 Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis December 2006 December 2008
NCT00399906 Completed Phase 2 A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis August 2007 April 2009
NCT00407342 Completed N/A Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis. February 2004 September 2004
NCT00407979 Completed Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis July 2005 February 2009
NCT00408187 Completed Phase 3 Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients December 2006 December 2008
NCT00417820 Completed Phase 1 Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis. November 2006 November 2007
NCT00436540 Completed Phase 4 A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam March 2006 January 2007
NCT00437216 Completed Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis February 2006 July 2006
NCT00437619 Completed Phase 4 A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis. February 2007 August 2009
NCT00443326 Completed Phase 2 AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects March 2007 May 2010
NCT00454584 Completed Phase 3 An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis March 2007 January 2009
NCT00462072 Completed Phase 4 Centocor Microarray Study of Patients March 2007 August 2010
NCT00482170 Completed Phase 3 Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept September 2007 September 2009
NCT00504270 Completed Phase 2 A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis. July 2007 September 2009
NCT00513370 Completed Phase 3 A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis September 2007
NCT00527072 Completed Phase 3 PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept July 2007 October 2009
NCT00537212 Completed N/A Study of the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy June 2007 August 2008
NCT00550030 Completed N/A Etanercept Plus UVB-311nm Phototherapy in Psoriasis August 2006 December 2010
NCT00555178 Completed Regulatory T Cells (Tregs) in Polymorphic Light Eruption March 2008 December 2014
NCT00563524 Completed Phase 1 Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis December 2007 June 2010
NCT00566722 Completed Phase 3 Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy January 2008 April 2009
NCT00578370 Completed Phase 1/Phase 2 Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test November 2007 April 2008
NCT00581165 Completed Phase 4 Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept February 2006 August 2007
NCT00581555 Completed Phase 4 Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy October 2007 November 2009
NCT00585650 Completed Phase 1/Phase 2 Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet May 2007 May 2008
NCT00602823 Completed Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva) February 2006 May 2006
NCT00604682 Completed Phase 2 Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis January 1, 2005 December 1, 2005
NCT00606450 Completed Phase 2 Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis April 1, 2006 May 1, 2007
NCT00617994 Completed Phase 2 Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis August 31, 2007 May 31, 2009
NCT00638261 Completed N/A Primary UVB-311nm and Adalimumab in Psoriasis Patients March 2008 August 2011
NCT00643526 Completed Early Phase 1 A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector December 2007 January 2008
NCT00645814 Completed Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis March 2003
NCT00645892 Completed Phase 2 Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis November 2003
NCT00645905 Completed Phase 2 Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis June 2003
NCT00646191 Completed Phase 2 Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis March 2003
NCT00647400 Completed Phase 2/Phase 3 Adalimumab in Adult Japanese Subjects With Psoriasis April 2006 April 2010
NCT00655564 Completed Phase 4 Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis May 2008 January 2010
NCT00658788 Completed Phase 3 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis March 2008 January 2009
NCT00663052 Completed Phase 4 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis June 2008 January 2010
NCT00669123 Completed Phase 4 Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis
NCT00669214 Completed Phase 4 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp February 2008 January 2009
NCT00678210 Completed Phase 2 Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis July 2008 August 2009
NCT00678561 Completed Phase 2 Topical CP-690,550 For Chronic Plaque Psoriasis October 13, 2008 July 24, 2009
NCT00679731 Completed Phase 3 A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis April 2008 November 2009
NCT00684593 Completed Phase 2 A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009) June 1, 2007 October 1, 2007
NCT00686595 Completed Phase 4 A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133) October 1, 2007 October 1, 2009
NCT00686686 Completed Phase 3 Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED) December 2007 April 2009
NCT00687362 Completed Phase 2 A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528) May 30, 2006 November 11, 2008
NCT00687401 Completed Phase 3 A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612) June 2006 May 2009
NCT00688519 Completed Phase 3 Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies March 2008 December 2008
NCT00689481 Completed Phase 3 Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies March 2008 October 2008
NCT00692172 Completed Phase 3 Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis December 2001 November 2004
NCT00708708 Completed Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings June 2008 December 2013
NCT00710489 Completed Potential Research Study Participant Registry May 2008 September 5, 2018
NCT00715975 Completed Phase 2/Phase 3 Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis July 2008 August 2010
NCT00716144 Completed Phase 2 Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis June 1, 2006 May 1, 2007
NCT00723437 Completed Phase 4 Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis January 2005 July 2008
NCT00723528 Completed Phase 3 An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis March 2008 March 2010
NCT00725348 Completed Phase 2 An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis April 2004 December 2006
NCT00725452 Completed Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900) October 2006 June 2010
NCT00727298 Completed Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) February 2006 August 2011
NCT00735787 Completed Phase 4 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet August 2008 September 2009
NCT00747344 Completed Phase 3 A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis December 2008 March 2010
NCT00748020 Completed Phase 4 Narrow-Band UVB-Therapy in Psoriasis January 2003 January 2007
NCT00749398 Completed Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047) September 2007 September 2010
NCT00755196 Completed Phase 2 Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis September 2008 December 2008
NCT00759161 Completed Phase 2 Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis November 2007 March 2008
NCT00760669 Completed An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants May 2007 April 2011
NCT00762658 Completed Phase 1 A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test November 30, 2007 December 7, 2007
NCT00763204 Completed Phase 1 A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test February 29, 2008 March 7, 2008
NCT00763529 Completed Phase 4 Elocon vs Fluticasone in Localized Psoriasis (P03197) January 1, 2003 January 1, 2005
NCT00763555 Completed Phase 2 Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis September 2008 March 2009
NCT00769184 Completed N/A Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis October 2008 April 2009
NCT00773734 Completed Phase 2 Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) September 1, 2008 May 20, 2015
NCT00778700 Completed Phase 2 A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis October 28, 2008 June 26, 2009
NCT00779675 Completed Assessment of Long-Term Infliximab for Psoriasis (P05319) October 2008 August 2012
NCT00789880 Completed Phase 2 Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3 December 2008 December 2009
NCT00791765 Completed Phase 4 Moderate to Severe Plaque Psoriasis With Scalp Involvement October 2008 March 2010
NCT00800982 Completed N/A Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis October 2008 March 2012
NCT00808223 Completed Phase 2 Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis April 2009 February 2012
NCT00820950 Completed Phase 2 A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis May 31, 2007 April 30, 2009
NCT00823693 Completed Phase 2 Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis
NCT00823914 Completed Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life December 2008 December 2013
NCT00824889 Completed N/A Exploratory Study of Natural Killer Cells in Human Skin February 2009 November 2011
NCT00830817 Completed Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis July 2007 June 2008
NCT00842153 Completed Phase 4 Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam November 2007 January 2008
NCT00848055 Completed Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis December 2008
NCT00867100 Completed Phase 1 Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 December 2007 September 2009
NCT00870285 Completed N/A Ustekinumab Plus UVB-311nm in Psoriasis March 2009 April 2011
NCT00879944 Completed Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index May 2009 July 2012
NCT00893126 Completed Premature Coronary Artery Disease (CAD) in Severe Psoriasis November 2009 August 2016
NCT00894777 Completed Study Evaluating Management of Patients With Moderate and Severe Psoriasis March 2009 November 2009
NCT00895375 Completed Prevalence of Sleep Disturbances in Psoriasis October 2009 December 2014
NCT00925574 Completed Phase 1 A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis June 4, 2009 October 11, 2010
NCT00929578 Completed Phase 2 Fluphenazine Hydrochloride for Psoriasis November 2008 January 2011
NCT00930384 Completed A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis November 2009 April 2016
NCT00930592 Completed Peds Metabolic Syndrome in Psoriasis April 2009 December 2012
NCT00932113 Completed Phase 4 Mechanism of Action Study for Psoriasis June 2009 May 1, 2017
NCT00937027 Completed Phase 1 Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis June 2009 April 2010
NCT00940862 Completed Phase 4 Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis July 2009 August 2011
NCT00941278 Completed Phase 2 An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis July 2009 April 2010
NCT00967538 Completed Phase 4 Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments September 2009 July 2014
NCT00971477 Completed Phase 2 Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis August 2009 June 2010
NCT00975637 Completed Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis December 2009 September 2010
NCT00987870 Completed Phase 1/Phase 2 Safety and Efficacy of BFH772 in Psoriasis Patients September 2009
NCT00992394 Completed Phase 4 Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept January 2010 April 2013
NCT00995969 Completed Phase 2 CT 327 in the Treatment of Psoriasis Vulgaris March 2010 January 2011
NCT00998829 Completed Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis May 2010 May 2012
NCT01001208 Completed Phase 3 The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis November 2009 February 2011
NCT01008995 Completed Phase 3 A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis October 2009 July 2011
NCT01018134 Completed Phase 2 Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study November 2009 May 2010
NCT01019200 Completed Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis November 2009 April 2016
NCT01029405 Completed Phase 2 Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis November 2009 June 2010
NCT01039142 Completed Phase 4 Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis March 2008 March 2009
NCT01043393 Completed Phase 2 Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study February 2010 June 2010
NCT01045395 Completed Phase 1 Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis September 2009 November 2010
NCT01045577 Completed Phase 2 A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis September 2005 February 2008
NCT01047943 Completed Phase 1/Phase 2 STA-21 Topical Efficacy on Psoriasis June 2007 April 2008
NCT01053819 Completed Phase 4 Can We Miss Pigmented Lesions in Psoriasis Patients? September 2007 April 2012
NCT01059773 Completed Phase 4 A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate October 2009 August 2011
NCT01077128 Completed Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab September 2009 September 2012
NCT01077882 Completed Phase 4 Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis January 2010 April 2012
NCT01079988 Completed Phase 4 Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence February 2004 April 2005
NCT01081730 Completed Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database February 9, 2010 September 29, 2017
NCT01083121 Completed Surveillance of Humira Injection in Korean Patients April 2007 June 2012
NCT01090427 Completed Phase 3 A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) May 2010 January 2014
NCT01094093 Completed Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis April 11, 2010 July 26, 2011
NCT01096862 Completed Phase 2 A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis March 23, 2010 July 27, 2011
NCT01098721 Completed Phase 2 A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks January 2010 November 2010
NCT01100034 Completed Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis November 19, 2010 September 24, 2018
NCT01107457 Completed Phase 2 A Study in Participants With Moderate to Severe Psoriasis April 2010 July 2016
NCT01119339 Completed Phase 2 Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis July 2010 September 2010
NCT01126619 Completed A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis May 2010 September 2011
NCT06458868 Completed N/A An Open-label Controlled Trial: Effectiveness of Balneotherapy in Palmoplantar Psoriasis and Contact Dermatitis. June 1, 2014 October 1, 2023
NCT00001420 Completed Study of Psoriatic Arthritis March 1995 January 2006
NCT00001422 Completed Phase 2 A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis June 1995 April 2000
NCT00001797 Completed Phase 2 Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis January 1999 September 2000
NCT00002143 Completed Phase 3 Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
NCT00002286 Completed N/A A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
NCT00005660 Completed The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases October 1977 November 2001
NCT00005781 Completed Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles May 2000 September 2000
NCT00005922 Completed N/A Conditioning, the Placebo Effect, and Psoriasis August 2000 July 2006
NCT00006275 Completed N/A Study of Topical Calcitriol in Children With Psoriasis July 2000 July 2000
NCT00006276 Completed Phase 2 Micellar Paclitaxel to Treat Severe Psoriasis September 2000 October 2002
NCT00007293 Completed Phase 1/Phase 2 Scalp Psoriasis Treatment With a Fiber Optic Comb August 2000 July 2002
NCT00026741 Completed Research in Skin Inflammation March 2001 January 2002
NCT00050648 Completed Phase 1/Phase 2 To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris October 1997 April 2008
NCT00050661 Completed Phase 1/Phase 2 To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris October 1997 April 2008
NCT00078819 Completed Phase 3 Etanercept (Enbrel®) in Psoriasis - Pediatrics September 8, 2004 June 1, 2007
NCT00096603 Completed Phase 3 A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g October 2002 July 2004
NCT00096928 Completed A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) March 2005 October 2009
NCT00096980 Completed Phase 4 A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies February 2001 May 2004
NCT00097240 Completed An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW) January 2005 September 2009
NCT00098189 Completed Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis July 2004
NCT00106834 Completed Phase 3 A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis October 2004
NCT00106847 Completed Phase 3 A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis January 2003 July 2005
NCT00109252 Completed Phase 3 A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g January 2002 April 2003
NCT00109317 Completed Phase 3 A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy September 2002 February 2003
NCT00110981 Completed Phase 4 Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis March 2005 March 2006
NCT00111111 Completed Phase 3 An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis
NCT00111124 Completed Phase 4 Enbrel® in Psoriatic Arthritis
NCT00111436 Completed Phase 3 Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects April 2003 July 2005
NCT00111449 Completed Phase 3 Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis June 2003
NCT00113542 Completed Phase 2 A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris June 2004 June 2005
NCT00115076 Completed Phase 3 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis August 4, 2003 April 6, 2011
NCT00116181 Completed Phase 3 Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis October 2004
NCT00121615 Completed Phase 3 Study of Etanercept in the Treatment of Psoriasis in Adult Subjects October 2004
NCT02538341 Completed Phase 2 Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) May 2016 December 2020
NCT02548052 Completed Phase 1 Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis October 22, 2015 February 19, 2016
NCT02552316 Completed N/A Psoriasis Microbiome and Phototherapy December 2014 October 2020
NCT02555709 Completed Phase 1/Phase 2 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients August 2015 March 2016
NCT02559622 Completed Phase 3 Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab April 2014 April 2016
NCT02564042 Completed Phase 2 A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis November 23, 2015 October 5, 2016
NCT02574091 Completed Phase 1 Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients November 26, 2015 February 19, 2017
NCT02576197 Completed N/A Intervention Study to Evaluate a Probiotic in Mild to Moderate Psoriasis Patients May 2015 September 2016
NCT02576678 Completed Phase 2 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis October 13, 2015 July 29, 2019
NCT02581345 Completed Phase 3 Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis September 2015 April 4, 2017
NCT02592018 Completed Phase 4 Immunologic Response to Secukinumab in Plaque Psoriasis October 2016 December 2018
NCT02595970 Completed Phase 3 Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis May 20, 2015 February 9, 2017
NCT02599415 Completed N/A Anti-psoriatic Effect of TL01 Light Therapy September 2014 December 2014
NCT02602925 Completed Phase 4 Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity March 2016 July 20, 2018
NCT02618616 Completed Phase 2 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis January 11, 2016 December 22, 2016
NCT02622386 Completed Phase 2 The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis August 11, 2016 April 6, 2020
NCT02626793 Completed A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions August 3, 2015 June 14, 2018
NCT02630901 Completed Phase 1 Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis March 17, 2016 February 28, 2018
NCT02635204 Completed Phase 3 A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis December 2015 July 2016
NCT02652065 Completed N/A Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis February 8, 2016 July 16, 2018
NCT02652494 Completed Observational Study of Apremilast in Patients With Psoriasis in The Netherlands February 22, 2016 June 30, 2020
NCT02655705 Completed Phase 4 Comparison Study of Psoriasis Severity Assessment Tools August 2014 March 2016
NCT02660580 Completed Phase 3 MSB11022 in Moderate to Severe Chronic Plaque Psoriasis February 16, 2016 December 18, 2017
NCT02672852 Completed Phase 3 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment February 29, 2016 July 26, 2018
NCT02684357 Completed Phase 3 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis March 2016 September 2017
NCT02684370 Completed Phase 3 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis February 2016 September 2017
NCT02690142 Completed Phase 1 A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035 February 2016 January 10, 2018
NCT02694523 Completed Phase 3 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis March 2016 August 2017
NCT02698475 Completed Phase 3 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age May 2016 October 2020
NCT02713711 Completed N/A Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis December 2013 June 2014
NCT02714322 Completed Phase 3 MYL-1401A Efficacy and Safety Comparability Study to Humira® June 2015 March 2017
NCT02718898 Completed Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis April 2016 February 21, 2018
NCT02733874 Completed Phase 4 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. April 2015
NCT02740218 Completed A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice June 30, 2016 October 27, 2021
NCT02748863 Completed Phase 3 Study of Secukinumab With 2 mL Pre-filled Syringes December 12, 2016 June 8, 2018
NCT02750800 Completed Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) April 7, 2016 April 3, 2018
NCT02752672 Completed Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis March 2016 November 2016
NCT02762955 Completed Phase 3 Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis December 2016 October 15, 2018
NCT02762994 Completed Phase 2 International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis June 2016 May 2017
NCT02763969 Completed Phase 1 Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis May 18, 2016 December 15, 2016
NCT02772601 Completed Phase 1 This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis September 15, 2016 September 22, 2017
NCT02776033 Completed Phase 2 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis August 30, 2016 January 4, 2018
NCT02785159 Completed Phase 2 Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis February 2016 December 2016
NCT02785172 Completed Phase 2 Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis April 2016 January 2017
NCT02785185 Completed Phase 2 Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis June 2016 January 2017
NCT02796014 Completed Assessment of Dermatologic Family Impact Scale in the Parents of Children With Psoriasis May 2016 March 2017
NCT02801435 Completed Phase 1 Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis September 17, 2016 June 8, 2017
NCT02808559 Completed N/A PASIMAT: Automatic Measure of PASI November 2014 May 2015
NCT02849795 Completed N/A Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis April 2014 October 17, 2017
NCT02850900 Completed N/A Oral Psoriasis Treatment Adherence and Intervention Study April 2016 September 13, 2021
NCT02850965 Completed Phase 3 Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis August 17, 2016 January 17, 2018
NCT02872285 Completed Phase 2 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis December 5, 2016 June 22, 2017
NCT02896868 Completed Phase 1 A Study of LY3041658 in Participants With Skin Diseases November 8, 2016 March 19, 2019
NCT02905331 Completed Phase 3 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis February 28, 2017 February 6, 2018
NCT02908347 Completed Phase 2 Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients May 2016 February 2017
NCT02917434 Completed N/A Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis April 2016 October 6, 2021
NCT02922192 Completed Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis January 1, 2012 June 1, 2020
NCT02929745 Completed N/A Single Cell Genomics of Psoriatic Skin July 1, 2016 December 9, 2020
NCT02931838 Completed Phase 2 Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis November 15, 2016 November 16, 2017
NCT02933528 Completed Phase 2 Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS July 11, 2016 November 27, 2017
NCT02934412 Completed Phase 1 A Study of SHR-1314 in Healthy Subjects August 22, 2016 June 30, 2017
NCT02940002 Completed Phase 1 BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test October 12, 2016 March 17, 2017
NCT02951533 Completed Phase 3 A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis December 12, 2016 February 6, 2019
NCT02954081 Completed APremilast After FumaRic Acid Ester Treatment January 26, 2017 August 15, 2022
NCT02955693 Completed Phase 1 Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008 September 2016 November 2016
NCT02978690 Completed Phase 1 Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis December 19, 2016 January 10, 2018
NCT02983981 Completed Phase 4 Topical Psoriasis Study for Patients Receiving Biologic Therapy March 2016 October 2016
NCT02985736 Completed Phase 4 Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray September 2016 January 27, 2017
NCT02993471 Completed Phase 1 A Study of Ixekizumab in Participants With Plaque Psoriasis December 22, 2016 November 21, 2017
NCT02995473 Completed Phase 2 Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis February 8, 2017 May 28, 2018
NCT03000075 Completed Phase 2 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis December 2, 2016 June 20, 2018
NCT03004768 Completed Phase 1 Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants January 26, 2017 February 27, 2017
NCT03004846 Completed Phase 1/Phase 2 A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis February 13, 2017 May 5, 2017
NCT03007810 Completed Phase 1 Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects December 2016 June 2018
NCT03018509 Completed Phase 1 Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects December 2016 June 20, 2017
NCT03022045 Completed Phase 3 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis January 26, 2017 November 19, 2020
NCT03022617 Completed Phase 4 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis January 2017 September 29, 2022
NCT03047395 Completed Phase 3 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) February 27, 2017 November 29, 2023
NCT03048721 Completed N/A Skin Tape Harvesting for Transcriptomics Analysis August 14, 2017 September 24, 2018
NCT03050294 Completed Phase 4 Evaluating Treatment Resistant Dermatitis TaroIIR February 1, 2017 June 1, 2017
NCT03051347 Completed N/A Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments September 2016 June 30, 2020
NCT03058744 Completed Phase 1 Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis April 2015 January 2017
NCT03062618 Completed Phase 1 A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis February 20, 2017 February 8, 2018
NCT03069144 Completed Phase 1/Phase 2 Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis January 6, 2012 May 28, 2012
NCT03073213 Completed Phase 1 A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris April 13, 2017 May 14, 2019
NCT03074656 Completed N/A The Norwegian Drug Monitoring Study March 1, 2017 December 14, 2020
NCT03080545 Completed Phase 4 Enstilar in Combination With Biologic Agents May 1, 2017 October 30, 2017
NCT03082729 Completed Phase 4 Vascular Inflammation in Psoriasis - Apremilast April 24, 2017 August 17, 2021
NCT03084146 Completed N/A The Role of Food Sensitivity in Psoriasis August 28, 2017 October 22, 2023
NCT03090100 Completed Phase 3 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis April 27, 2017 September 20, 2018
NCT03097003 Completed A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium April 6, 2017 December 20, 2018
NCT03099083 Completed Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab March 31, 2017 April 5, 2019
NCT03123471 Completed Phase 3 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp May 16, 2017 January 9, 2019
NCT03131570 Completed Phase 2 Safety and Efficacy of Secukinumab in Mild Psoriasis May 23, 2017 June 21, 2021
NCT03135548 Completed Phase 2 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients May 30, 2017 November 14, 2018
NCT03173144 Completed Chronic Inflammatory Disease, Lifestyle and Treatment Response September 21, 2017 April 30, 2021
NCT03210259 Completed Phase 3 The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis July 10, 2017 April 16, 2019
NCT03217734 Completed Phase 2/Phase 3 MAP Study: Methotrexate and Adalimumab in Psoriasis April 10, 2017 December 31, 2018
NCT03219437 Completed Phase 3 A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis July 30, 2018 November 26, 2021
NCT03223012 Completed Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service November 15, 2017 February 28, 2019
NCT03236870 Completed A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China September 8, 2017 August 25, 2020
NCT03253666 Completed Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component) January 2017 May 2018
NCT03254784 Completed Phase 1 A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation September 13, 2017 November 15, 2017
NCT03255382 Completed Phase 3 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy August 22, 2017 July 6, 2018
NCT03262727 Completed Phase 1 The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients September 1, 2017 December 19, 2017
NCT03265613 Completed Phase 1/Phase 2 Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis September 24, 2017 November 28, 2019
NCT03279978 Completed Phase 1 This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357 January 9, 2018 August 30, 2018
NCT03284879 Completed Post-Marketing Surveillance Study of OTEZLA September 5, 2017 March 20, 2022
NCT03334136 Completed N/A The Effect of Vitamin D Supplementation on Psoriasis Severity November 24, 2017 May 13, 2019
NCT03337022 Completed Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis January 4, 2018 April 26, 2019
NCT03339089 Completed Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases May 18, 2018 July 8, 2021
NCT03343639 Completed Phase 2 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis November 1, 2017 November 12, 2018
NCT03358914 Completed The PsoTeenQOL - Preliminary Reliability and Validity February 20, 2018 January 31, 2019
NCT03374527 Completed Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis October 16, 2014 June 13, 2018
NCT03381625 Completed Phase 2 Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis January 2, 2018 July 24, 2021
NCT03384745 Completed Phase 2 A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis July 31, 2018 March 26, 2020
NCT03392168 Completed Phase 1/Phase 2 Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis December 11, 2017 May 2, 2018
NCT03392311 Completed Phase 1/Phase 2 Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis July 23, 2019 March 19, 2020
NCT03399526 Completed Phase 1 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat February 11, 2013 May 31, 2013
NCT03399708 Completed Immune Metabolic Associations in Psoriatic Arthritis June 12, 2017 October 25, 2019
NCT03403036 Completed Phase 4 Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies October 31, 2017 August 18, 2018
NCT03406117 Completed Phase 4 A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests April 1, 2016 July 21, 2016
NCT03409211 Completed N/A Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis December 12, 2017 September 30, 2019
NCT03418493 Completed Phase 1 A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis January 30, 2018 July 29, 2019
NCT03419910 Completed Phase 1 An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants March 5, 2018 May 4, 2018
NCT03421197 Completed Phase 2 A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) January 25, 2018 March 30, 2020
NCT03423004 Completed N/A Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin January 11, 2019 July 11, 2019
NCT03431974 Completed Phase 2 Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis November 1, 2018 January 11, 2021
NCT03440541 Completed N/A Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment August 4, 2015 April 8, 2016
NCT03440736 Completed Phase 4 Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome February 28, 2018 June 3, 2022
NCT03445013 Completed Phase 1 A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis October 13, 2017 February 6, 2018
NCT03448081 Completed Phase 2 Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene February 12, 2018 December 10, 2018
NCT03455166 Completed N/A Identification of New Prognostic Markers in Psoriatic Arthritis May 2015 September 2017
NCT03469336 Completed Phase 1 Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis April 24, 2018 March 20, 2019
NCT03475914 Completed Characterization of Cutaneous Microbiota in the Psoriasis Pathogenesis October 13, 2016 November 21, 2017
NCT03478787 Completed Phase 3 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis May 8, 2018 July 8, 2020
NCT03482011 Completed Phase 3 A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis April 24, 2018 January 16, 2020
NCT03492632 Completed Ovarian Reserve in Patients With Psoriasis October 25, 2017 July 3, 2018
NCT03493269 Completed Phase 1 A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis April 16, 2018 February 5, 2021
NCT03506477 Completed Phase 4 Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color May 21, 2018 September 25, 2019
NCT03511755 Completed N/A 12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN March 12, 2018 July 24, 2018
NCT03518047 Completed Phase 3 Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation July 19, 2018 February 11, 2020
NCT03531528 Completed N/A Aggressive Weight Loss Program in Chronic Plaque Psoriasis May 21, 2018 October 29, 2018
NCT03535194 Completed Phase 3 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) June 26, 2018 June 3, 2020
NCT03539419 Completed Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain June 12, 2018 October 31, 2020
NCT03542994 Completed Phase 1 A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis April 24, 2019 January 3, 2020
NCT03580278 Completed Phase 1 A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2 November 13, 2019 September 22, 2020
NCT03587194 Completed Phase 4 Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis July 23, 2018 July 1, 2019
NCT03594877 Completed N/A Effect of Sublimated Mare Milk Supplement on Gut Microbiome in Psoriasis Patients April 1, 2018 December 30, 2020
NCT03597620 Completed Phase 4 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis November 7, 2018 December 13, 2022
NCT03611751 Completed Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis July 26, 2018 November 30, 2020
NCT03622021 Completed Phase 1 A Study of AK111 in Healthy Subjects August 14, 2018 February 20, 2020
NCT03624127 Completed Phase 3 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis August 7, 2018 September 2, 2020
NCT03626714 Completed Early Phase 1 Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study October 16, 2018 January 5, 2019
NCT03635099 Completed Phase 2 This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is September 17, 2018 May 26, 2021
NCT03706209 Completed Phase 2 Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis February 27, 2018 June 12, 2019
NCT03718299 Completed Phase 4 A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis July 16, 2019 November 5, 2021
NCT03718884 Completed Phase 1 A Study of Mirikizumab in Participants With Plaque Psoriasis October 23, 2018 October 28, 2019
NCT03721172 Completed Phase 3 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy March 11, 2019 July 24, 2020
NCT03724292 Completed Phase 1 An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers August 1, 2015 March 8, 2016
NCT03726489 Completed N/A Light Treatment Effectiveness (LITE) Study March 1, 2019 December 30, 2023
NCT03733353 Completed Phase 1 A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis November 19, 2018 October 29, 2021
NCT03738163 Completed N/A A Clinical Investigation With Epaderm® Cream April 1, 2019 June 17, 2020
NCT03757013 Completed A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France September 25, 2018 September 10, 2021
NCT03767114 Completed N/A Estimation of Level of ERAP1 Expression in Lesional and Non Lesional Skin of Psoraitic Patients and Healthy Controls. January 2017 December 2018
NCT03768284 Completed Genetic Analysis of Pediatric Psoriasis October 17, 2018 December 30, 2021
NCT03774875 Completed Phase 4 A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life March 28, 2019 November 3, 2021
NCT03777436 Completed Phase 3 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis February 11, 2019 February 9, 2022
NCT03798236 Completed Phase 1 Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers. December 10, 2018 May 31, 2019
NCT03816917 Completed Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral June 1, 2019 July 28, 2022
NCT03831646 Completed Clinical, Psychological and Genetic Characteristics in Dermatological Patients January 20, 2019 July 30, 2019
NCT03832738 Completed Phase 2 Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis January 17, 2019 March 13, 2020
NCT03848806 Completed Phase 2 Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis February 29, 2016 September 5, 2016
NCT03850483 Completed Phase 2 Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis April 8, 2019 April 20, 2021
NCT03865030 Completed N/A The Inner Ear Function in Psoriatic Patients March 1, 2019 April 1, 2022
NCT03873142 Completed N/A The Effectiveness of a Mindful Parenting Intervention for Parents of Children With Psoriasis and Parents of Children With Eczema October 19, 2018 August 22, 2019
NCT03873415 Completed Phase 1 Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males January 25, 2019 May 1, 2019
NCT03875482 Completed Phase 3 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis May 13, 2019 July 15, 2020
NCT03875508 Completed Phase 3 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis June 4, 2019 August 25, 2020
NCT03895372 Completed Phase 2 A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis June 27, 2019 November 26, 2020
NCT03922607 Completed Phase 1 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis June 11, 2019 April 13, 2021
NCT03924427 Completed Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis April 10, 2019 March 24, 2021
NCT03925441 Completed Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea June 25, 2019 August 6, 2019
NCT03941184 Completed Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity January 1, 1995 November 10, 2020
NCT03955861 Completed Ultrasound Enthesitis Response in Psoriatic Arthritis February 14, 2019 July 17, 2021
NCT03960450 Completed Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis April 23, 2019 January 28, 2020
NCT03964168 Completed An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers July 31, 2019 March 3, 2020
NCT03998683 Completed Phase 3 A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis September 3, 2019 November 30, 2021
NCT04013867 Completed Identification of the Best Self-questionnaire to Diagnose Depression in Patients With Psoriasis (DePsoVal) July 22, 2019 June 7, 2021
NCT04074070 Completed Prevalence of Sonographic Abnormalities of Joints and Entheses in Psoriasis Patients With or Without Musculoskeletal Complains February 18, 2020 September 30, 2020
NCT04102241 Completed Phase 2 Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis May 30, 2019 July 21, 2021
NCT04106297 Completed Phase 1 A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970 September 10, 2019 March 5, 2021
NCT04119557 Completed Phase 1 A Study of LY3471851 in Participants With Psoriasis November 26, 2019 July 21, 2021
NCT04136314 Completed N/A Impact of Decision-Framing in Psoriasis October 21, 2019 January 31, 2020
NCT04149587 Completed A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen September 30, 2019 March 30, 2022
NCT04167462 Completed Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea November 25, 2019 January 7, 2022
NCT04173039 Completed N/A Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis August 29, 2018 April 24, 2019
NCT04239521 Completed The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata October 1, 2020 November 28, 2022
NCT04250792 Completed Phase 1 Efficacy of Low Dose Naltrexone in Psoriasis January 1, 2019 September 30, 2019
NCT04271735 Completed N/A Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis August 26, 2020 December 19, 2022
NCT04274595 Completed N/A Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis February 13, 2020 June 20, 2022
NCT04275024 Completed N/A Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients April 1, 2020 February 3, 2021
NCT04277832 Completed Evaluating of New Screening Tool for Arthritis* in Psoriasis February 21, 2020 January 13, 2021
NCT04308616 Completed Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis July 20, 2020 April 27, 2022
NCT04316533 Completed Work Stress and Impact of Pruritus on Quality of Life March 9, 2020 June 30, 2020
NCT04316585 Completed Phase 1 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants September 28, 2020 October 12, 2021
NCT04371185 Completed Phase 1 Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects August 8, 2020 April 19, 2021
NCT04410237 Completed Early Phase 1 Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System November 4, 2020 May 19, 2023
NCT04418791 Completed N/A Modified Intermittent Fasting in Psoriasis October 17, 2020 February 23, 2022
NCT04439526 Completed A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis June 10, 2020 November 21, 2023
NCT04459780 Completed N/A Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis October 25, 2016 November 13, 2017
NCT04513847 Completed PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis August 13, 2020 October 6, 2020
NCT04537468 Completed N/A Development of a Method to Measure mRNA Levels in Skin Samples May 11, 2017 October 2, 2019
NCT04549870 Completed Phase 2 Efficacy of Roflumilast in the Treatment of Psoriasis January 1, 2021 December 12, 2022
NCT04560647 Completed Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions December 3, 2020 April 14, 2023
NCT04571567 Completed Phase 4 A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis December 2, 2019 February 22, 2022
NCT04581044 Completed Impact of COVID-19 on Psoriasis Practice September 17, 2020 October 23, 2020
NCT04587362 Completed The Diagnostic Ultrasound Enthesitis Tool (DUET) Study March 17, 2021 February 27, 2023
NCT04603027 Completed Phase 2 A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis September 21, 2020 December 6, 2021
NCT04633616 Completed N/A Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients November 16, 2020 January 19, 2022
NCT04655313 Completed Phase 2 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) November 30, 2020 January 12, 2022
NCT04673786 Completed Phase 3 A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis January 11, 2021 May 12, 2022
NCT04711343 Completed Phase 1 Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects June 8, 2022 June 5, 2023
NCT04713592 Completed Phase 3 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement February 26, 2021 April 20, 2023
NCT04728165 Completed Anti-Inflammatory Effects of Time-Restricted Feeding June 9, 2021 July 28, 2023
NCT04744363 Completed Phase 1 Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) May 25, 2021 March 19, 2022
NCT04745429 Completed N/A Non-pharmacological Mitigation of Psoriasis February 19, 2020 October 6, 2020
NCT04746911 Completed Phase 2 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) March 1, 2021 May 11, 2022
NCT04750993 Completed Comparison of the Frequency of Subclinic Synovitis in the Distal Interphalangeal Joints of the Hand in Psoriasis Patients October 1, 2014 June 1, 2015
NCT04761627 Completed Phase 3 A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis March 24, 2021 February 28, 2023
NCT04765332 Completed Evaluation of the Sensitivity and Specificity of a Novel Quality of Life Tool to Assess the Treatment Satisfaction in Psoriasis Patients December 4, 2020 March 13, 2023
NCT04776629 Completed Phase 2 A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors June 30, 2021 November 11, 2022
NCT04780516 Completed Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care April 26, 2021 January 2, 2024
NCT04808739 Completed Adalimumab Biosimilar in Clinical Practice June 1, 2020 February 28, 2021
NCT04826536 Completed A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan June 25, 2021 October 8, 2021
NCT04837235 Completed Phase 1 Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects April 29, 2021 August 25, 2021
NCT04839328 Completed Phase 3 A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis January 20, 2022 July 28, 2023
NCT04841187 Completed Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis September 6, 2021 December 31, 2023
NCT04843631 Completed Phase 1 Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults April 1, 2021 December 8, 2021
NCT04848194 Completed N/A Pleiotropic Role of TRPV1 in Psoriasis Inflammation December 22, 2021 January 24, 2024
NCT04894890 Completed A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China September 26, 2021 December 15, 2023
NCT04908475 Completed Phase 4 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy June 9, 2021 April 20, 2023
NCT04914429 Completed Phase 4 A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis August 25, 2021 September 26, 2023
NCT04927195 Completed Phase 1 Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma February 23, 2021 February 28, 2022
NCT04930042 Completed Phase 3 Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis June 3, 2021 October 11, 2022
NCT04967508 Completed Phase 3 A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis July 6, 2021 November 25, 2022
NCT04975295 Completed Phase 1 A Study of LY3361237 in Participants With Psoriasis July 27, 2021 November 29, 2022
NCT05003531 Completed Phase 2 A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis September 23, 2021 January 17, 2023
NCT05051943 Completed A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response September 29, 2020 January 20, 2023
NCT05065762 Completed Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment October 1, 2021 February 7, 2022
NCT05096364 Completed Phase 2 A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis April 28, 2021 February 1, 2023
NCT05098600 Completed The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic October 15, 2021 December 20, 2022
NCT05118425 Completed Dietary Perceptions and Practices in Chinese Psoriasis Patients November 1, 2020 September 1, 2021
NCT05125458 Completed Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Diseases. April 1, 2021 November 30, 2022
NCT05190419 Completed Phase 2 Study to Assess the Efficacy and Safety of Orismilast in Psoriasis December 30, 2021 December 20, 2022
NCT05203354 Completed Phase 4 Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin September 1, 2018 August 15, 2021
NCT05252533 Completed Phase 1 A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis May 24, 2022 January 26, 2024
NCT05283876 Completed N/A Excimer Light in Psoriasis March 10, 2022 March 30, 2023
NCT05320159 Completed Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab) February 3, 2021 March 31, 2021
NCT05406908 Completed Phase 4 Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases June 15, 2022 May 1, 2023
NCT05428202 Completed Phase 1 Phase I Study of GN-037 Cream for Psoriasis March 28, 2022 September 30, 2022
NCT05448352 Completed Asking People With Psoriasis About Lifestyle and Eating June 18, 2022 January 8, 2024
NCT05453942 Completed Phase 1 A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis July 12, 2022 February 9, 2023
NCT05458531 Completed Monitoring of Inflammatory Conditions June 28, 2022 February 8, 2023
NCT05461456 Completed Phase 1 Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% April 1, 2022 October 16, 2022
NCT05504317 Completed Phase 1 A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis May 19, 2020 March 9, 2021
NCT05513014 Completed Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis March 21, 2021 August 31, 2021
NCT05514353 Completed Phase 1 A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream December 28, 2021 January 12, 2023
NCT05522816 Completed Phase 1 KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis October 27, 2015 March 10, 2021
NCT05523011 Completed Phase 1 Safety and Tolerability Study of MSC Exosome Ointment March 8, 2022 April 5, 2022
NCT05547490 Completed A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis October 31, 2022 April 28, 2023
NCT05680740 Completed Phase 4 A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis January 12, 2023 May 25, 2023
NCT05683054 Completed Phase 4 A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated August 11, 2020 August 22, 2022
NCT05684744 Completed Phase 2/Phase 3 Roflumilast Versus Methotrexate in Psoriasis January 9, 2023 May 14, 2023
NCT05706870 Completed Phase 2 Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis December 7, 2022 March 3, 2024
NCT05718921 Completed Phase 1 A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers April 8, 2023 December 14, 2023
NCT05734482 Completed Phase 1 Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers February 15, 2023 July 3, 2023
NCT05758402 Completed N/A A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study) October 20, 2022 June 30, 2023
NCT05770271 Completed N/A The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and Psoriasis January 29, 2023 January 20, 2024
NCT05789576 Completed Phase 4 A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region March 13, 2023 July 19, 2023
NCT05796245 Completed A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis December 1, 2023 March 14, 2024
NCT05943405 Completed The Disease Severity In Patients With Psoriasis June 1, 2022 December 30, 2022
NCT05957120 Completed Subclinical Impairment of Cardiovascular System in Patients With Psoriasis January 3, 2022 November 30, 2022
NCT06032858 Completed Phase 4 Efficacy and Safety of Apremilast in Psoriasis March 6, 2022 August 10, 2023
NCT06033742 Completed Phase 1 A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects November 13, 2021 March 24, 2023
NCT06043752 Completed Phase 4 Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis March 10, 2022 August 5, 2023
NCT06073613 Completed Periodontal Status in Patients With Chronic Skin Diseases January 20, 2023 April 28, 2023
NCT06075394 Completed Hypertension, Antihypertensive Medication Use, and Risk of Psoriasis November 1, 2021 October 1, 2023
NCT06103695 Completed Phase 4 Vtama in Psoriasis Patients Being Treated With Biologics. February 27, 2023 October 18, 2023
NCT06172426 Completed Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry November 17, 2022 December 7, 2022
NCT06329258 Completed Phase 4 Combination of Sotyktu and Enstilar for Plaque Psoriasis December 6, 2022 November 13, 2023
NCT06361212 Completed Phase 1 Ethoximod Pharmacokinetics In Healthy Subjects September 1, 2022 January 12, 2024
NCT06408454 Completed Interleukin- 17 (IL-17), Bcl-3, and NF-kappa-B Inhibitor Zeta (IκBζ) Expression Levels in the Psoriasis Patients February 1, 2023 August 15, 2023
NCT00001371 Completed A Pilot Study of Topical Antiflammin-2 for Psoriasis December 1993 December 2000
NCT01133561 Completed N/A Pioglitazone in Psoriasis- A Clinical and Molecular Study. January 2010 August 2010
NCT01137032 Completed Phase 4 Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population June 2004 August 2005
NCT01137188 Completed N/A Effect of Weight Loss on Psoriasis June 2010 September 2011
NCT01139580 Completed Phase 3 The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis May 2010 December 2010
NCT01139918 Completed Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis June 2010 July 2014
NCT01147874 Completed Phase 4 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice August 2010 July 2011
NCT01154101 Completed Phase 2 Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis June 7, 2010 November 9, 2011
NCT01155570 Completed Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) February 2010 July 2012
NCT01162252 Completed N/A Improving Psoriasis Through Health and Well-Being March 2010 December 2013
NCT01169987 Completed Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life May 2010 March 2015
NCT01170715 Completed N/A Psoriasis Inflammation and Systemic Co Morbidities July 13, 2010 September 9, 2013
NCT01177800 Completed Phase 3 A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis February 2009 September 2010
NCT01181570 Completed Phase 4 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea September 2010 September 2011
NCT01186744 Completed Phase 3 A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis September 2010 January 2013
NCT01187264 Completed Phase 4 Dose Ranging Study to Compare the Efficacy and Safety of Methotrexate in Plaque Type Psoriasis August 2008 September 2009
NCT01205880 Completed Phase 4 Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis December 2009 January 2010
NCT01206387 Completed Phase 3 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis August 2010 January 2011
NCT01206660 Completed Phase 3 Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis August 2010 January 2011
NCT01208090 Completed Phase 2 ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis October 31, 2010 November 30, 2012
NCT01225731 Completed Phase 2 A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003) October 25, 2010 October 24, 2012
NCT01229085 Completed Phase 3 Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis September 2006 October 2007
NCT01233583 Completed Regulatory T-cells in Psoriasis Patients as Targets for Therapy June 2010 September 2013
NCT01235442 Completed Phase 3 Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis September 2010 December 2011
NCT01235728 Completed Phase 1 A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022) November 1, 2010 April 1, 2011
NCT01241591 Completed Phase 3 A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis November 2010 January 2013
NCT01245140 Completed Phase 2 Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis April 26, 2011 April 16, 2014
NCT01246583 Completed Phase 2 CP-690-550 Ointment For Chronic Plaque Psoriasis February 16, 2011 November 29, 2011
NCT01247818 Completed Phase 2 Randomized Study of PH-10 for Psoriasis December 2010 March 2012
NCT01254240 Completed Phase 2 Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases December 2010 December 2015
NCT01262534 Completed A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis. October 2010 June 2011
NCT01265823 Completed Phase 4 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis October 2010 February 2012
NCT01276639 Completed Phase 3 A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis March 2011 April 2013
NCT01276847 Completed Phase 1 A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206) March 2011 December 2011
NCT01283698 Completed Phase 2 Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis January 2011 March 2011
NCT01300052 Completed Phase 2 AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis January 26, 2011 June 6, 2011
NCT01309737 Completed Phase 3 A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis March 2011 April 2013
NCT01313221 Completed Phase 3 Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis April 2011 May 2013
NCT01316224 Completed Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment April 2011 April 2014
NCT01320293 Completed N/A Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. March 2011 March 2015
NCT01328366 Completed Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab May 2011 May 2014
NCT01356004 Completed Phase 4 Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis January 2010 November 2010
NCT01356758 Completed Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents March 2011 November 2015
NCT01360944 Completed Phase 2 Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test May 2011 June 2011
NCT01384630 Completed Phase 2 Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis September 30, 2011 August 31, 2012
NCT01387815 Completed Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis August 16, 2011 June 29, 2018
NCT01404338 Completed Phase 1 Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis June 2011
NCT01422434 Completed Phase 3 LEO 90105 Ointment in Japanese Subjects With Psoriasis July 2011 April 2012
NCT01425138 Completed Systematic Review And Meta-Analysis Of Psoriasis Treatments. June 2009 June 2011
NCT01435265 Completed N/A Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab January 2010 April 2012
NCT01451346 Completed Phase 1/Phase 2 Study in Patients With Mild to Moderate Psoriasis January 2008 August 2011
NCT01460069 Completed N/A The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis October 2011 May 2013
NCT01462643 Completed Phase 2 Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test August 2011 September 2011
NCT01465061 Completed A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis February 2011 August 2011
NCT01474512 Completed Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis November 16, 2011 September 20, 2018
NCT01483599 Completed Phase 2 A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis November 10, 2011 August 5, 2013
NCT01484587 Completed Phase 1 A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis August 22, 2011 April 11, 2013
NCT01488201 Completed Phase 1 A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis November 2011 September 2012
NCT01490632 Completed Phase 2 A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis December 2011 August 2014
NCT01510951 Completed Phase 1 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis August 2011 October 2012
NCT01511315 Completed Phase 4 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment March 2012 December 2014
NCT01519089 Completed Phase 3 A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis March 2012 January 2014
NCT01538342 Completed N/A Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis July 2012 July 2016
NCT01539213 Completed Phase 1 Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg February 2012 January 2013
NCT01539915 Completed Phase 1 Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients April 2007
NCT01550744 Completed Phase 3 A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis March 2012 July 2015
NCT01553058 Completed Phase 4 Vascular Inflammation in Psoriasis Trial (The VIP Trial) July 2012 October 27, 2016
NCT01563068 Completed Phase 1 Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis April 2012 August 2015
NCT01577550 Completed Phase 1 Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis April 2012 May 2014
NCT01582932 Completed Phase 1 Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis April 2013 August 2018
NCT01585233 Completed Phase 2 A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis April 30, 2012 January 7, 2015
NCT01597245 Completed Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) May 18, 2012 June 18, 2019
NCT01610596 Completed Phase 2 A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis November 2011 February 2012
NCT01617018 Completed Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis July 2012 September 5, 2021
NCT01624233 Completed Phase 3 A Study in Japanese Participants With Moderate-to-Severe Psoriasis June 2012 September 2017
NCT01646177 Completed Phase 3 A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) July 28, 2012 July 22, 2019
NCT01687582 Completed N/A Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients January 2012 March 2013
NCT01690299 Completed Phase 3 Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis October 1, 2012 April 4, 2016
NCT01700985 Completed Phase 2 A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis May 2012 March 2013
NCT01702493 Completed Phase 1 A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers October 30, 2012 December 5, 2012
NCT01714284 Completed N/A Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis February 2011 January 2012
NCT01714544 Completed Phase 4 Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis October 2012
NCT01722214 Completed Phase 4 Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis November 2012 January 2016
NCT01722812 Completed Phase 2 Cromoglicate in Psoriasis November 2012 May 2013
NCT01736696 Completed Phase 1 Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis November 2002 April 2004
NCT01745133 Completed Phase 4 Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis January 2013 August 2014
NCT01761019 Completed Phase 4 A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy January 2013 September 2014
NCT01763424 Completed Phase 2/Phase 3 Nicotinamide in the Treatment of Psoriasis July 2011 December 2012
NCT01778569 Completed The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI) January 22, 2013
NCT01782664 Completed Phase 2 A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis March 1, 2013 March 24, 2014
NCT01782924 Completed Phase 3 A Phase 3 Clinical Study of KHK4827 March 2013 February 2015
NCT01782937 Completed Phase 3 An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis February 2013 December 2014
NCT01802580 Completed Early Phase 1 Using an Internet Study to Improve Adherence for Psoriasis Patients October 2012 April 2016
NCT01812954 Completed Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis March 2013 June 2014
NCT01815424 Completed Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis December 2013 July 2015
NCT01826201 Completed Phase 2 Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis March 2013 August 2013
NCT01831466 Completed Phase 2 Tofacitinib Ointment For Chronic Plaque Psoriasis May 2013 September 2014
NCT01836939 Completed Phase 1 Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis March 2013 September 2014
NCT01837420 Completed Phase 2 A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis November 2012 November 2014
NCT01844973 Completed Phase 1 Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients April 2013 August 2013
NCT01866592 Completed Phase 4 Vascular Inflammation in Psoriasis - Extension Study April 2013 October 27, 2016
NCT01873677 Completed Phase 3 Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis June 2013 April 2015
NCT01878461 Completed Phase 3 Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis June 2013 May 2015
NCT01894373 Completed Phase 1/Phase 2 Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis June 2015 June 2017
NCT01899755 Completed Phase 1 A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. July 10, 2013 April 3, 2014
NCT01901705 Completed Phase 2 A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis February 2013 January 2014
NCT01908595 Completed Phase 3 Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis August 2013 May 2015
NCT01916629 Completed N/A Photocil (Topical) for the Treatment of Psoriasis Vulgaris August 2013 December 2014
NCT01920906 Completed N/A Comparative Analysis of Small and Large Plaque Psoriasis January 2014 June 2015
NCT01931644 Completed At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions July 2013 April 2024
NCT01937260 Completed Phase 1 Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects September 2013 December 2014
NCT01947491 Completed Phase 3 A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis November 2013 January 2015
NCT01947933 Completed Phase 1 A Safety Study of Mirikizumab (LY3074828) October 2013 February 2015
NCT01952015 Completed Phase 3 Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) August 21, 2013 March 15, 2016
NCT01961609 Completed Phase 3 Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. October 9, 2013 July 12, 2016
NCT01964443 Completed Clinical Assessment and Psychosocial Impact of Psoriasis September 2013 November 2015
NCT01967069 Completed Phase 3 A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis November 2013 July 2014
NCT01970488 Completed Phase 3 Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis October 18, 2013 March 18, 2015
NCT01971346 Completed Phase 4 The Immunological Basis for Treatment Resistance to Anti-TNF Treatments March 13, 2014 November 1, 2017
NCT01984775 Completed Phase 1 A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects October 30, 2013 July 2, 2014
NCT01987609 Completed Phase 2 Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques July 2015 February 2018
NCT01988103 Completed Phase 2 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis July 9, 2013 December 15, 2015
NCT01988506 Completed Phase 2 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases January 6, 2014 April 1, 2021
NCT01989689 Completed Phase 2 Etanercept and Vascular Function in Psoriasis August 2010 September 2013
NCT01991197 Completed Phase 2 Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. April 2014 January 2016
NCT01993433 Completed Phase 2 A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis October 2013 March 2014
NCT01999868 Completed Phase 2 Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris March 19, 2014 March 1, 2018
NCT02054481 Completed Phase 2 BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab February 2014 July 2015
NCT02075632 Completed Phase 2 Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream September 2006 November 2006
NCT02097173 Completed Phase 1 Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen May 2013
NCT02101216 Completed Phase 1 Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers March 2014 October 2014
NCT02107482 Completed N/A Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis December 2011 December 2014
NCT02111499 Completed Phase 1/Phase 2 Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test March 2014 June 2014
NCT02131324 Completed Phase 2 DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis May 8, 2014 August 11, 2016
NCT02147600 Completed Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients January 9, 2014 April 10, 2014
NCT02155192 Completed An Exploratory Genetic Study in Participants With Psoriasis March 2014 September 2014
NCT02156466 Completed Phase 1 Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects August 2014 August 2015
NCT02162472 Completed Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis July 2015 December 31, 2021
NCT02168244 Completed N/A Reduction of Pain Caused by Biologic Drugs in Psoriasis May 2014 March 2016
NCT02173301 Completed Phase 2 A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis June 2014 August 2015
NCT02173392 Completed Phase 1 A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab September 2014 December 2014
NCT02180464 Completed Phase 2 A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis June 2014 December 2014
NCT02187172 Completed Phase 4 Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U) July 2014 September 11, 2018
NCT02191007 Completed N/A Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis November 2013 May 2014
NCT02191020 Completed N/A Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis February 2013 October 2013
NCT02193919 Completed A Single-Center, Prospective, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy March 2007 May 2008
NCT02195349 Completed Phase 1 A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis July 30, 2014 March 7, 2018
NCT02196701 Completed Phase 3 Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study August 5, 2014 March 17, 2017
NCT02203032 Completed Phase 3 A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab October 7, 2014 May 24, 2016
NCT02203851 Completed Phase 2 Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis November 20, 2014 September 4, 2018
NCT02207231 Completed Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis November 26, 2014 June 17, 2020
NCT02207244 Completed Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment November 3, 2014 July 1, 2020
NCT02209753 Completed Phase 2 BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis June 2001
NCT02271971 Completed N/A Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis October 2014 October 2015
NCT02274363 Completed A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis April 10, 2012 May 31, 2013
NCT02295865 Completed Phase 2 A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis November 17, 2014 March 11, 2016
NCT02303509 Completed Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject August 2013 February 2014
NCT02305953 Completed Cytokines and Vascular Inflammation in Psoriasis October 2014 October 2014
NCT02310204 Completed N/A Therapeutic Education Program in Psoriasis May 2011 June 2014
NCT02313922 Completed Phase 4 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate November 2014 August 2018
NCT02322086 Completed Phase 2 A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 January 2015 June 2017
NCT02322580 Completed An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients January 2015 November 2016
NCT02325219 Completed Phase 3 An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis December 19, 2014 February 8, 2019
NCT02326272 Completed Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) December 15, 2014 September 12, 2018
NCT02326298 Completed Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) December 16, 2014 October 24, 2018
NCT02330380 Completed Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation April 2013 December 2016
NCT02346240 Completed Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) February 11, 2015 December 17, 2018
NCT02347501 Completed Phase 2 Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) November 2013 December 2016
NCT02358135 Completed N/A Collaborative Connected Health (CCH) for PCORI February 2, 2015 August 20, 2017
NCT02362789 Completed Phase 3 Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers January 4, 2015 July 15, 2016
NCT02366273 Completed Diabetes and Psoriasis February 1, 2015 June 30, 2018
NCT02376478 Completed On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection December 2009 January 2011
NCT02382081 Completed N/A A Randomized Control Trial of Patient-initiated Hospital Follow-up for Patients With Psoriasis May 2, 2015 February 17, 2018
NCT02387801 Completed Phase 3 A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis April 2015 August 2016
NCT02397382 Completed Phase 1 Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis June 18, 2015 August 31, 2016
NCT02407041 Completed Phase 2 An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis September 2015 March 2018
NCT02417792 Completed The Association Between Psoriasis and Intestinal Bacterial Population May 14, 2015 February 18, 2019
NCT02432027 Completed Phase 1/Phase 2 Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test June 2015 September 2015
NCT02432040 Completed Phase 2 Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis February 2013 November 2013
NCT02451839 Completed An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) July 6, 2015 December 5, 2017
NCT02457000 Completed Sleep, Circadian Rhythm & Skin Health March 2015 August 2020
NCT02458677 Completed Phase 1 Single Ascending Dose Study of PRX003 in Healthy Subjects May 2015 February 2016
NCT02474082 Completed Phase 3 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. April 2015 June 2016
NCT02483234 Completed Phase 2 Psoriasis-Arthritis & Bone Program May 31, 2015 September 30, 2018
NCT02489643 Completed N/A Individualized Medical Training and Calcipotriol and Betamethasone Dipropionate Gel in Plaque Psoriasis May 2014
NCT02503059 Completed Etanercept Survival in Elderly Population November 2014 February 2015
NCT04862286 Enrolling by invitation Phase 3 Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 July 24, 2021 February 5, 2029
NCT04190758 Enrolling by invitation GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden January 1, 2020 December 21, 2069
NCT05971992 Enrolling by invitation N/A INulin-type Fructans-induced Gut Microbiota Modulation Impact on GUT-SKIN Axis Parameters in Psoriasis February 2, 2023 February 2027
NCT03254667 Enrolling by invitation LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis July 25, 2017 November 2031
NCT02707341 Enrolling by invitation The Corrona Psoriasis (PSO) Registry April 2015 December 2100
NCT05084417 Enrolling by invitation A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions June 9, 2023 January 15, 2026
NCT06050330 Not yet recruiting N/A CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study September 30, 2023 September 30, 2024
NCT06398652 Not yet recruiting Phase 3 Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis May 31, 2024 December 31, 2025
NCT06416566 Not yet recruiting N/A Low-Dose Enoxaparin in Psoriasis May 15, 2024 October 1, 2024
NCT05725876 Not yet recruiting Phase 1 Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis. July 1, 2023 June 30, 2025
NCT06376474 Not yet recruiting Phase 1 To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage April 2024 December 2024
NCT06324695 Not yet recruiting N/A Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases March 2024 March 2025
NCT05555797 Not yet recruiting Phase 4 Excimer Laser With Topical Agents in Psoriasis Vulgaris October 30, 2022 September 30, 2023
NCT06055699 Not yet recruiting Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis March 1, 2024 March 1, 2028
NCT06126718 Not yet recruiting Phase 1 Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects November 2023 August 2024
NCT06213688 Not yet recruiting N/A Involvement of Pollutants in Atopic Dermatitis and Psoriasis March 2024 March 2025
NCT05601492 Not yet recruiting Early Phase 1 Adherence to Otezla July 2024 February 2025
NCT06380153 Not yet recruiting Phase 1 To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment April 2024 December 2024
NCT06402760 Not yet recruiting Early Phase 1 Comprehensive Intervention of Diabetes and Psoriasis Comorbidity Prevention and Control July 1, 2024 December 31, 2025
NCT06021405 Not yet recruiting N/A Koebner's Phenomenon in Psoriasis and Lichen Planus September 15, 2023 June 30, 2025
NCT06180473 Not yet recruiting Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream January 1, 2024 June 30, 2024
NCT05863273 Not yet recruiting Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT） May 20, 2023 December 31, 2024
NCT06281106 Not yet recruiting Phase 2/Phase 3 TYK2 Inhibition in Paradoxical Psoriasis April 2024 August 2025
NCT05571696 Recruiting N/A Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases October 27, 2022 September 30, 2024
NCT05391178 Recruiting N/A Improving Disease Severity August 9, 2022 September 2024
NCT06242847 Recruiting Role of Insulin Action in Psoriasis Pathogenesis February 2, 2024 May 2025
NCT04717466 Recruiting Phase 4 Brain Changes in Psoriasis After Secukinumab Treatment June 29, 2021 August 31, 2024
NCT06077331 Recruiting Phase 2 A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis September 28, 2023 August 31, 2024
NCT05632042 Recruiting N/A Response of Metabolic Syndrome and Sexual Dysfunction to Lifestyle Changes in Men With Psoriasis October 16, 2022 April 16, 2023
NCT05399433 Recruiting N/A Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis June 30, 2022 September 1, 2026
NCT03661866 Recruiting A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC December 21, 2018 December 2050
NCT04629950 Recruiting Phase 2 Rimegepant in Moderate Plaque-type Psoriasis January 19, 2021 August 15, 2024
NCT05132231 Recruiting Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity October 22, 2021 June 2024
NCT04630652 Recruiting Phase 4 Risankizumab Long-term Remission Study April 7, 2021 July 28, 2027
NCT05184699 Recruiting N/A The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis November 1, 2022 January 30, 2024
NCT06247319 Recruiting Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece April 29, 2024 October 26, 2027
NCT06061471 Recruiting Phase 2 To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis September 14, 2023 November 2024
NCT05200598 Recruiting Cardiovascular Risk Predictors in Patients With Psoriasis October 1, 2021 September 1, 2024
NCT04170244 Recruiting Study of Skin Microbiome in AD and PS Patients April 17, 2019 April 1, 2026
NCT06257641 Recruiting N/A Impact of the Mediterranean Diet on Patients With Psoriasis October 4, 2023 April 30, 2025
NCT06073119 Recruiting Phase 2 A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis October 26, 2023 May 8, 2025
NCT05570955 Recruiting N/A Deucravacitinib Adherence Study July 24, 2023 March 2025
NCT05258838 Recruiting Tunisian National Registry on Psoriasis July 12, 2022 July 1, 2024
NCT05270733 Recruiting Phase 4 Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics November 10, 2022 December 31, 2024
NCT03816345 Recruiting Phase 1 Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer July 16, 2019 August 31, 2024
NCT04693936 Recruiting N/A Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis February 2, 2021 January 2024
NCT03827876 Recruiting Phase 4 Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis January 16, 2019 December 15, 2019
NCT05295979 Recruiting Phase 2 Chinese Medicine for Patients With Psoriasis March 20, 2023 August 31, 2024
NCT05307809 Recruiting N/A Cytokine Expression in Psoriasis Patients With and Without Joint Involvement August 17, 2022 August 18, 2024
NCT05725057 Recruiting Phase 1/Phase 2 Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis November 30, 2023 December 2024
NCT03840928 Recruiting PatientSpot Formerly Known as ArthritisPower April 1, 2015 March 1, 2025
NCT03125655 Recruiting Regulation of Inflammatory Genes in Psoriasis April 22, 2014 April 28, 2027
NCT05555953 Recruiting Effect of Long-term Psoriasis on Patients' Life - CORONATE January 26, 2023 December 31, 2024
NCT05728489 Recruiting Phase 1 A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis March 9, 2023 April 11, 2025
NCT05503875 Recruiting N/A Immunoclassification of Psoriasis: a Strategy for Precision Medicine January 1, 2023 December 31, 2027
NCT03218488 Recruiting A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis August 29, 2017 August 31, 2032
NCT04119102 Recruiting Phase 4 Duobrii in Combination With Biologics October 14, 2019 September 1, 2020
NCT05506644 Recruiting N/A Biofeedback for Psoriasis June 7, 2022 March 31, 2023
NCT05744466 Recruiting A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis September 30, 2022 December 10, 2027
NCT03240809 Recruiting Phase 4 An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects January 24, 2020 July 2024
NCT06277635 Recruiting N/A Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases February 1, 2024 April 2025
NCT04751396 Recruiting Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors April 20, 2022 April 15, 2025
NCT04433442 Recruiting Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis August 4, 2020 March 30, 2025
NCT04347473 Recruiting Phase 4 ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. April 6, 2020 March 1, 2021
NCT06319781 Recruiting A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo December 15, 2023 May 2025
NCT05633264 Recruiting A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan December 5, 2022 May 31, 2025
NCT04785027 Recruiting Phase 1/Phase 2 Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis March 17, 2021 September 30, 2024
NCT01706692 Recruiting Swiss Dermatology Network of Targeted Therapies (SDNTT) July 2011 June 2033
NCT05536726 Recruiting Phase 3 A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis January 3, 2023 June 23, 2024
NCT05635266 Recruiting Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives October 26, 2021 October 2025
NCT05858528 Recruiting HIPPOCRATES Prospective Observational Study June 27, 2023 June 30, 2026
NCT04809571 Recruiting N/A Non-invasive Photoacoustic Imaging of Skin Inflammatory Disorders With Machine Learning-assisted Scoring February 22, 2021 January 31, 2024
NCT03358693 Recruiting Molecular Signatures in Inflammatory Skin Disease January 20, 2017 December 31, 2028
NCT04465838 Recruiting Chinese Psoriasis Real World Evidence Research July 8, 2020 July 30, 2030
NCT03361215 Recruiting Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis March 16, 2015 December 31, 2030
NCT04818385 Recruiting Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan May 31, 2021 December 31, 2024
NCT01797224 Recruiting OTIS Autoimmune Diseases in Pregnancy Project March 2012 October 2026
NCT05866614 Recruiting A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps January 13, 2023 March 2027
NCT05883371 Recruiting IMPACT - AndHealth Autoimmune Research Registry June 8, 2023 May 22, 2028
NCT05894759 Recruiting N/A The Impact of Different Relaxation Techniques on Psoriasis Patients With an Elevated Psychological Stress Level June 2023 August 2024
NCT03392337 Recruiting N/A An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients November 7, 2017 January 1, 2020
NCT05908240 Recruiting N/A Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis June 15, 2023 October 2025
NCT05928169 Recruiting Determinants of Chronic Inflammatory Skin Disease Trajectories May 1, 2023 December 31, 2032
NCT05590247 Recruiting N/A Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis July 21, 2022 September 1, 2025
NCT01848028 Recruiting PsoBest - The German Psoriasis Registry January 2008 December 2032
NCT04864886 Recruiting Metabolic Profiling of Immune Responses in Immune-mediated Diseases August 10, 2021 June 30, 2027
NCT06448689 Recruiting Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and Psoriasis March 12, 2024 June 2026
NCT04191395 Recruiting Evolution and Treatments of Chronic Inflammatory Systemic Diseases December 11, 2019 December 2029
NCT04912401 Recruiting the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis December 4, 2020 December 4, 2025
NCT05959070 Recruiting An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO) November 9, 2023 August 1, 2024
NCT05970978 Recruiting Phase 2 A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics August 28, 2023 February 28, 2025
NCT04950218 Recruiting The Psoriasis Echo Study September 1, 2021 October 1, 2030
NCT05636839 Recruiting N/A UVB-induced Treg Cells Exert Antigen-specific Suppression Through LAG-3 January 25, 2022 December 2025
NCT04372277 Recruiting Phase 4 Taltz in Combination With Enstilar for Psoriasis April 28, 2020 March 30, 2021
NCT04535999 Recruiting Phase 4 Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) February 7, 2022 December 2025
NCT05642182 Recruiting Phase 1 Study of SFA002 in Patients With Mild to Moderate Psoriasis Plaques March 31, 2022 July 31, 2024
NCT06027034 Recruiting N/A Effectiveness of a Digital Health Application for Psoriasis September 4, 2023 March 2025
NCT05644782 Recruiting N/A Dietary Approach to Mild-to-moderate Psoriasis January 1, 2023 October 31, 2024
NCT05621369 Recruiting Psorcast Mobile Study January 1, 2022 January 31, 2027
NCT05004727 Recruiting Phase 4 Multi-Center PAMPA Study February 16, 2022 March 1, 2026
NCT05064748 Recruiting Phase 4 Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults June 1, 2021 September 30, 2024
NCT02075697 Recruiting Spanish Registry of Systemic Treatments in Psoriasis October 2008 October 2025
NCT02103361 Recruiting Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project November 2013 December 2025
NCT06216691 Recruiting N/A Smart Phone Delivered Cognitive Behavioral Therapy for Adults With Psoriasis and Co-Morbid Depression Symptoms January 1, 2024 December 31, 2024
NCT06230588 Recruiting Phase 1 A Clinical Trial of TQH3906 Capsules in Healthy Volunteers February 2, 2024 October 2024
NCT02144857 Recruiting Phase 4 Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis May 30, 2014 December 31, 2023
NCT06049810 Recruiting Phase 3 IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment October 12, 2023 December 31, 2025
NCT05111210 Recruiting Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis December 14, 2021 December 2024
NCT05122039 Recruiting ProspectIve Cohort psoriASiS fOllow-up (PICASSO) October 20, 2021 October 19, 2032
NCT06101706 Recruiting N/A Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients March 11, 2024 January 2025
NCT05442190 Recruiting Phase 2 Topical SGX302 for Mild-to-Moderate Psoriasis December 14, 2022 June 2025
NCT06102356 Recruiting Impact of Clinical and Psychological Factors on Treatment Satisfaction in Psoriatic Patients in Biological Therapy September 13, 2023 June 15, 2024
NCT02572700 Recruiting Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis September 2015 September 2025
NCT05451199 Recruiting Phase 1 A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis July 29, 2022 December 31, 2023
NCT05589298 Recruiting The Study of Koebner in Patients With Psoriasis and Psoriatic Arthritis October 19, 2022 October 17, 2024
NCT06399432 Recruiting N/A Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors October 18, 2022 July 1, 2026
NCT06110676 Recruiting Phase 3 A Study to Evaluate the Efficacy and Safety of LZM012 August 21, 2023 June 2025
NCT04271540 Recruiting Phase 4 MIcrovascular dysfuNction In Moderate-severe Psoriasis April 4, 2020 January 2025
NCT06170840 Recruiting Phase 2 A Study of QY101 Ointment in Subjects With Plaque Psoriasis May 17, 2023 April 30, 2024
NCT03987763 Recruiting Phase 4 A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis October 22, 2019 June 2024
NCT03988439 Recruiting Phase 4 A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis March 24, 2021 June 2024
NCT06156280 Recruiting Phase 1 A Clinical Study of TQH2929 in Healthy Adult Subjects November 21, 2023 April 2025
NCT05480917 Recruiting N/A Value Based Healthcare in Psoriasis March 1, 2023 September 1, 2025
NCT04246372 Recruiting Phase 2 Tofacitinib for Immune Skin Conditions in Down Syndrome October 21, 2020 December 2024
NCT05500794 Recruiting N/A Meditation in Inflammatory Dermatosis November 15, 2022 May 15, 2025
NCT01368887 Suspended Phase 2 Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis April 2013 April 2014
NCT02394301 Suspended Efficacy of Novel Drug-combinations for Relief of Psoriasis February 2015 December 2015
NCT01261767 Terminated Phase 1 First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects April 2008 January 2011
NCT01948271 Terminated Phase 1 Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis July 2013 September 2014
NCT03179605 Terminated Phase 2 Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 May 2, 2017 June 3, 2020
NCT01018810 Terminated Phase 2 A Study for Adults With Plaque Psoriasis December 2009 August 2010
NCT03556202 Terminated Phase 3 A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) September 3, 2018 February 7, 2022
NCT01101100 Terminated Phase 2 Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis April 2010 September 2015
NCT05125679 Terminated Phase 4 Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis November 23, 2021 July 28, 2023
NCT01522742 Terminated Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study February 2012 January 2016
NCT03971825 Terminated Phase 1 A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis July 24, 2018 August 5, 2021
NCT04995783 Terminated Predicting Medication Response for Autoimmune Disease September 1, 2020 August 1, 2022
NCT03701763 Terminated Phase 3 Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis December 19, 2018 March 27, 2023
NCT00697034 Terminated Phase 4 Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin June 2006 December 2008
NCT00358670 Terminated Phase 3 Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563) May 2006 January 2009
NCT01493518 Terminated Phase 1 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis November 2011 June 2013
NCT02936492 Terminated Phase 1 BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study October 24, 2016 October 16, 2017
NCT00833053 Terminated Phase 3 Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) October 2009 April 2011
NCT03198390 Terminated Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions August 4, 2017 May 31, 2020
NCT02649270 Terminated Phase 1 Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis October 2014 October 2017
NCT01088698 Terminated N/A Golimumab Plus UVB-311nm in Psoriasis March 2010 October 2010
NCT05044234 Terminated Phase 2 A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis November 16, 2021 November 30, 2022
NCT01543204 Terminated Phase 4 Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab February 1, 2012 May 29, 2015
NCT00782613 Terminated Phase 2 Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis November 2008 March 2009
NCT00427609 Terminated Phase 2 Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications January 2007 November 2009
NCT00477191 Terminated N/A Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis May 2007 December 2013
NCT01856647 Terminated Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects February 2013 December 2015
NCT03145948 Terminated Phase 1 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis May 9, 2017 August 16, 2017
NCT00217009 Terminated Early Phase 1 Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases. March 2005 November 2008
NCT04870827 Terminated Effect of Chronic Inflammation on Myocardial Perfusion and Function June 7, 2021 May 18, 2022
NCT00954915 Terminated Phase 1/Phase 2 Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis December 2009 July 2010
NCT00356200 Terminated Phase 2 Fluphenazine Decanoate for Psoriasis July 2006 September 2008
NCT00143819 Terminated Phase 2 Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis September 2005 February 2010
NCT02786732 Terminated Phase 3 Study to Evaluate Broadlumab vs Placebo and Ustekinumab August 2012 October 2017
NCT02047851 Terminated N/A Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis October 2014 May 9, 2018
NCT04152382 Terminated Phase 1 A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis November 20, 2019 February 9, 2022
NCT03656627 Terminated Phase 1 Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease June 27, 2019 March 18, 2021
NCT02408159 Terminated Phase 4 Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy June 2016 March 2017
NCT02294981 Terminated N/A Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis January 2016 September 2017
NCT03768219 Terminated Phase 1 Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis March 18, 2019 June 30, 2020
NCT03835481 Terminated Phase 2 A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is March 18, 2019 July 27, 2021
NCT01163253 Terminated Phase 3 A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis September 2010 June 2016
NCT00470392 Terminated N/A Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis May 2007 July 2012
NCT00129415 Terminated Phase 1/Phase 2 Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions August 2000 January 2011
NCT05655299 Terminated Phase 2 VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis November 17, 2022 December 20, 2023
NCT01149252 Terminated Phase 4 Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis January 2011 March 2013
NCT03540160 Terminated Phase 3 Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) March 15, 2018 June 17, 2020
NCT01704599 Terminated Phase 1/Phase 2 Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis January 2009 May 2014
NCT01403012 Terminated BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis August 2011 December 4, 2015
NCT01708590 Terminated Phase 3 Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects August 2012 August 2015
NCT01947036 Terminated T and B Cell Responses in Autoimmune Diseases January 2014 October 2015
NCT03329885 Terminated Phase 1/Phase 2 A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis November 2, 2017 June 26, 2018
NCT00454701 Terminated Assessment and Tracking of Long-term Alefacept Safety June 2003 February 2012
NCT00714272 Terminated N/A Granulocytapheresis in Psoriasis February 18, 2008 January 2009
NCT04305327 Terminated Phase 3 Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis December 7, 2022 May 5, 2023
NCT04533737 Terminated Phase 4 Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab December 17, 2020 December 7, 2022
NCT01094717 Terminated N/A Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis January 2010 October 2011
NCT04275206 Unknown status N/A The Anti-inflammatory Effects of Harkány Medicinal Water June 1, 2020 November 30, 2023
NCT02910791 Unknown status The Role of Bacterial Toxins in Human Skin Disease February 20, 2019 December 2023
NCT04344574 Unknown status Serum Level of IL31,33 and 36 in Egyptian Paients With Psoriasis June 1, 2020 July 1, 2021
NCT02918123 Unknown status Phase 1 Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis January 17, 2018 December 2021
NCT04359628 Unknown status How Does Patients' Overall Assessment of Their Health Vary Across and Within Different Disease Groups? January 2002 September 2020
NCT00372580 Unknown status Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis August 2006 December 2007
NCT04414605 Unknown status Early Phase 1 Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis June 4, 2020 December 31, 2021
NCT02940561 Unknown status Phase 1 BE Study in Patients - Methotrexate Tablets August 2016 October 2016
NCT02944630 Unknown status N/A Psychotherapy for Patients With Psoriasis: Effects in Quality of Life October 2016 January 2020
NCT01223976 Unknown status Phase 4 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis November 2010 August 2011
NCT01228409 Unknown status Phase 4 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? October 2010
NCT02955576 Unknown status N/A Microneedle Patch for Psoriatic Plaques September 2016 November 2017
NCT00638469 Unknown status N/A UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis March 2008 December 2014
NCT04435730 Unknown status Use of Serum M2BP and MSUS to Predict Arthritis in Psoriatic Patients October 2020 December 2022
NCT02999698 Unknown status Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact February 2017 June 2017
NCT04469829 Unknown status Phase 4 Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome August 1, 2020 December 31, 2022
NCT04515732 Unknown status Phase 4 Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP) December 14, 2018 October 2021
NCT04555707 Unknown status Phase 4 The Maintenance Effect of Enstilar Foam in Combination With Otezla June 24, 2020 September 30, 2021
NCT00365625 Unknown status Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris July 2005 December 2007
NCT01352780 Unknown status Phase 3 Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters September 2011 June 2016
NCT01382784 Unknown status Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study May 2011
NCT01439425 Unknown status Phase 4 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis November 2011 November 2012
NCT04680624 Unknown status N/A Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients January 2021 January 2022
NCT03127462 Unknown status N/A A Nurse-led Individualized Educational Intervention May 1, 2017 August 2018
NCT01504113 Unknown status The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis July 2011 June 2015
NCT04722094 Unknown status Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study January 25, 2021 August 25, 2021
NCT03180866 Unknown status N/A Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis December 2016 March 2018
NCT04722640 Unknown status Phase 4 Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity January 25, 2021 January 31, 2022
NCT01604902 Unknown status miRNAs and mRNAs in Psoriasis March 2011 January 2016
NCT01628081 Unknown status Phase 3 The Effect of Alga Dunaliella Bardawil on Psoriasis June 2012 July 2014
NCT01657513 Unknown status N/A TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis June 2012
NCT01661127 Unknown status Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis June 2012 December 2015
NCT00295425 Unknown status Phase 2 CYA Versus MMF for Treatment of Moderate-Severe Psoriasis. May 2000 October 2006
NCT04792957 Unknown status JAK-STAT Signaling Pathway in Pyoderma Gangrenosum May 1, 2022 July 31, 2022
NCT01744327 Unknown status TL1A Expression in Psoriatic Skin December 2012
NCT03340155 Unknown status N/A Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases October 30, 2017 October 2022
NCT04811911 Unknown status Phase 4 Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum TWEAK Level in Psoriasis December 13, 2020 December 15, 2021
NCT04848649 Unknown status N/A Shortening Treatments Of Chronic Inflammatory Conditions April 2021 April 2024
NCT04904315 Unknown status Subjects Through the Application of the Mindera Kit Part 2 August 1, 2021 May 30, 2022
NCT01088165 Unknown status Phase 4 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis May 2010 May 2014
NCT03453190 Unknown status Phase 4 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis February 25, 2018 June 30, 2020
NCT00224562 Unknown status The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists February 2004
NCT04971239 Unknown status Phase 4 Topical Methotrexate Microemulsion in the Treatment of Plaque Psoriasis October 1, 2021 October 1, 2022
NCT03478280 Unknown status Phase 4 Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis September 15, 2018 March 15, 2020
NCT03483311 Unknown status N/A Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy March 1, 2018 September 2018
NCT03485560 Unknown status Early Phase 1 Revitalization of Damaged Skin Due to Chronic Skin Diseases May 1, 2018 January 1, 2019
NCT05010044 Unknown status N/A MBCT for Psoriasis Patients With Anxiety and Depression August 2021 January 2022
NCT03526705 Unknown status N/A The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis July 15, 2019 January 15, 2020
NCT05076812 Unknown status Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients October 2021 December 2022
NCT02122978 Unknown status N/A Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy in a Psoriasis Sample November 2013 May 2015
NCT03570346 Unknown status Phase 1 Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects July 10, 2018 December 1, 2018
NCT03577626 Unknown status Phase 1 A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers October 10, 2018 March 1, 2019
NCT03629379 Unknown status Phase 4 Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions September 1, 2018 July 1, 2021
NCT05125757 Unknown status N/A Lifestyle Modification in Psoriatic Patients With Fatty Liver September 13, 2021 March 15, 2022
NCT01011621 Unknown status Phase 3 Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis February 2010
NCT02205593 Unknown status N/A Haut-Tief Patient Education on Psoriasis and Eczema July 2012 December 2022
NCT05135312 Unknown status Phase 4 Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging August 9, 2021 August 8, 2022
NCT05144165 Unknown status Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines November 8, 2021 March 31, 2022
NCT02258282 Unknown status N/A Safety and Efficacy of Etanercept in Patients With Psoriasis May 2014 December 2022
NCT03745417 Unknown status Phase 1/Phase 2 Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis August 31, 2021 December 31, 2022
NCT05225493 Unknown status HIV Indicator Diseases in Hospital and Primary Care January 1, 2020 May 2024
NCT03765957 Unknown status Early Phase 1 Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells February 20, 2019 June 1, 2021
NCT05252741 Unknown status N/A Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis. February 20, 2022 September 2023
NCT00835315 Unknown status Prevalence of Psoriasis Alba in Psoriatic Patients January 2008
NCT01122095 Unknown status Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis April 2010 April 2011
NCT05311501 Unknown status N/A Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis. May 10, 2022 January 1, 2023
NCT02447068 Unknown status N/A Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis May 2015
NCT05326659 Unknown status N/A Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis April 2022 August 2023
NCT05401006 Unknown status Phase 4 Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients . June 5, 2021 June 5, 2023
NCT03888261 Unknown status N/A Mind-Body Approaches for Medical Conditions April 1, 2019 January 1, 2020
NCT03889938 Unknown status Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis April 1, 2019 May 2020
NCT05427175 Unknown status Phase 4 Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis January 10, 2022 September 15, 2023
NCT03904680 Unknown status Phase 4 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients April 2019 November 2019
NCT02550080 Unknown status Phase 4 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome July 2015 May 2019
NCT03927352 Unknown status Phase 3 The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis September 5, 2019 December 31, 2022
NCT03942185 Unknown status Phase 2 Chinese Herbal Medicine for Psoriasis Vulgaris: a Real World Study June 1, 2019 December 31, 2021
NCT00150930 Unknown status Phase 4 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness October 2002 March 2005
NCT03976622 Unknown status Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata June 3, 2019 June 3, 2023
NCT02644954 Unknown status Phase 3 Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis January 2016
NCT04039451 Unknown status Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt September 1, 2019 May 31, 2020
NCT00824980 Unknown status Phase 2 Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis January 2009 September 2009
NCT04071106 Unknown status Phase 2/Phase 3 Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial September 1, 2019 December 31, 2019
NCT02668341 Unknown status Cross Sectional Analysis of Healthcare for Psoriasis in 4 European Countries October 2015 December 2020
NCT04099979 Unknown status A Pilot Study to Explore the Role of Gut Flora in Psoriasis March 2, 2020 July 2023
NCT04117919 Unknown status Phase 2 Psoriasis、Indigo Naturalis、Chinese Medicine Medicated Bath October 5, 2019 March 3, 2020
NCT02701205 Unknown status Phase 3 Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis January 2015 December 2017
NCT04146558 Unknown status Phase 3 Ayurvedic Treatment Package in Plaque Psoriasis December 4, 2019 November 15, 2021
NCT04168619 Unknown status MTX-related Liver Toxicity in Psoriasis Patients, Using Ultrasound-based Techniques as a Diagnostic Tool June 10, 2019 July 12, 2021
NCT01132235 Unknown status Phase 4 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use April 2010 December 2010
NCT03979664 Withdrawn Early Phase 1 Iontophoresis in Psoriasis March 2021 December 2021
NCT02472717 Withdrawn Phase 2 Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study May 2015 October 2016
NCT03820934 Withdrawn N/A FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis February 10, 2019 May 15, 2019
NCT01137448 Withdrawn N/A The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients June 2010 May 2013
NCT01006096 Withdrawn Phase 2 Erlotinib for Treatment of Psoriasis
NCT02165657 Withdrawn N/A Excimer Laser, Serum Markers & Psoriasis September 2013 March 2017
NCT00004468 Withdrawn N/A Study of Topical Calcitriol or Oral Calcitriol in Patients With Psoriasis October 1998
NCT01903317 Withdrawn Evaluation of Vitamin D Levels in Psoriasis Patients June 2013 July 2015
NCT01900782 Withdrawn Phase 3 Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo. October 2013 June 2015
NCT04799990 Withdrawn Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting June 23, 2021 March 10, 2022
NCT01121081 Withdrawn Phase 3 The Effect of Algae Dunaliella Bardawil on Psoriasis (2) January 2010 January 2012
NCT03302390 Withdrawn Role of Chemokine and Chemokine Receptor in Psoriasis April 17, 2017 April 13, 2018
NCT03202004 Withdrawn Phase 3 GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis January 22, 2018 September 28, 2018
NCT03201978 Withdrawn Phase 1 A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects December 14, 2017 May 15, 2018
NCT01527097 Withdrawn Phase 3 Influence of Atorvastatin on Psoriasis Severity and Endothelial Function August 2012 April 2015
NCT01429870 Withdrawn Phase 4 Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis August 2011 August 2016
NCT04488185 Withdrawn Phase 4 An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound November 2, 2020 March 24, 2021
NCT02795416 Withdrawn Phase 3 Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population June 2016 March 2017
NCT02970331 Withdrawn Phase 2 A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis June 2019 December 2019
NCT04423471 Withdrawn Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis February 1, 2021 December 2022
NCT00377325 Withdrawn Phase 2 The Effectiveness of Lower Cyclosporine Doses for Psoriasis June 2007 September 2013
NCT02624544 Withdrawn Phase 4 Proton Pump Inhibitors Use in Patients With Psoriasis January 2016 December 2016
NCT04417114 Withdrawn Phase 4 SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE April 1, 2021 March 31, 2025
Disase is a (Disease Ontology)
DOID:37
Cross Reference ID (Disease Ontology)
EFO:0000676
Cross Reference ID (Disease Ontology)
GARD:10262
Cross Reference ID (Disease Ontology)
ICD10CM:L40
Cross Reference ID (Disease Ontology)
MESH:D011565
Cross Reference ID (Disease Ontology)
MIM:PS177900
Cross Reference ID (Disease Ontology)
NCI:C3346
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:156369008
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0033860
OMIM Phenotype Series Number (OMIM)
PS177900
ICD10 preferred id (Insert disease from ICD10)
D0009750
ICD10 class code (Insert disease from ICD10)
L40
MeSH unique ID (MeSH (Medical Subject Headings))
D011565